Shishir K. Maithel (@skmaithel) 's Twitter Profile
Shishir K. Maithel

@skmaithel

Professor of Surgery, Surgical Oncologist, @NorthwesternMed, Editor-in-Chief: @SurgOncInsight

ID: 1670517714509611008

calendar_today18-06-2023 19:44:24

180 Tweet

422 Followers

133 Following

Surgical Oncology Insight (@surgoncinsight) 's Twitter Profile Photo

In Press: Advances in surgery, imaging, and perioperative care are transforming the management of pancreatic masses, with minimally invasive techniques and personalized strategies improving outcomes ow.ly/8c3y50VWIyY Flavio G Rocha, MD, FACS, FSSO @SKMaithel

In Press: Advances in surgery, imaging, and perioperative care are transforming the management of pancreatic masses, with minimally invasive techniques and personalized strategies improving outcomes 

ow.ly/8c3y50VWIyY

<a href="/FlavioRochaMD/">Flavio G Rocha, MD, FACS, FSSO</a>
@SKMaithel
ECOG-ACRIN Cancer Research Group (@eaonc) 's Twitter Profile Photo

#ClinicalTrial EA2222/PUMP, led by Michael Lidsky, MD, FACS, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump

#ClinicalTrial EA2222/PUMP, led by <a href="/michael_lidsky/">Michael Lidsky, MD, FACS</a>, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump
AHPBA (@ahpba) 's Twitter Profile Photo

Join AHPBA Monday, 06/23, for Pushing the Envelope & the Next Frontier for HCC & Cholangiocarcinoma Register Today: tinyurl.com/374ttdun Adnan Alseidi Shishir K. Maithel

Join AHPBA Monday, 06/23, for Pushing the Envelope &amp; the Next Frontier for HCC &amp; Cholangiocarcinoma

Register Today: tinyurl.com/374ttdun

<a href="/HPB_Surgeon/">Adnan Alseidi</a> <a href="/skmaithel/">Shishir K. Maithel</a>
Surgical Oncology Insight (@surgoncinsight) 's Twitter Profile Photo

The study on SVC reconstruction during thymic tumor resection demonstrates an 88.2% graft patency rate. Preoperative SVC syndrome and elevated venous pressure were occlusion predictors, while collateral vessel formation may lead to graft failure ow.ly/QY0r50VXJlk

The study on SVC reconstruction during thymic tumor resection demonstrates an 88.2% graft patency rate. Preoperative SVC syndrome and elevated venous pressure were occlusion predictors, while collateral vessel formation may lead to graft failure

ow.ly/QY0r50VXJlk
ECOG-ACRIN Cancer Research Group (@eaonc) 's Twitter Profile Photo

In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: bit.ly/ea2222-pump cc: Michael Lidsky, MD, FACS

In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: bit.ly/ea2222-pump cc: <a href="/michael_lidsky/">Michael Lidsky, MD, FACS</a>
Surgical Oncology Insight (@surgoncinsight) 's Twitter Profile Photo

June Issue: Association of neighborhood #SocioeconomicStatus and #EthnicDiversity with receipt of adjuvant chemotherapy in stage III #ColonCancer : A population-based cohort study Adom Bondzi-Simpson, MD, MSc Julie Hallet Andrea Covelli Callisia Clarke MD Natalie Coburn ow.ly/7LAP50W8kfH @SKMaithel

ECOG-ACRIN Cancer Research Group (@eaonc) 's Twitter Profile Photo

#ClinicalTrial EA2222/PUMP, led by Michael Lidsky, MD, FACS, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump

#ClinicalTrial EA2222/PUMP, led by <a href="/michael_lidsky/">Michael Lidsky, MD, FACS</a>, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump
Surgical Oncology Insight (@surgoncinsight) 's Twitter Profile Photo

June Issue: Outcomes following #DiagnosticLaparoscopy in patients with #PeritonealCarcinomatosis deemed ineligible for cytoreduction and hyperthermic intraperitoneal chemotherapy ( #HIPEC ) due to disease burden Paula Marincola Smith, MD, PhD ow.ly/eTzL50W8YST @SKMaithel

Adom Bondzi-Simpson, MD, MSc (@bondzi23) 's Twitter Profile Photo

🎯 New in Surgical Oncology Insight: In 🇨🇦’s universal system, Patients with stage III colon cancer from: 🔹 lowest SES areas: 30% ↓ odds 🔹 most diverse areas: 28% ↓ odds of receiving adjuvant chemo. Equity in care ≠ equity in access. 📊👇 Temerty Medicine U of T Public Health Julie Hallet

🎯 New in <a href="/SurgOncInsight/">Surgical Oncology Insight</a>:
In 🇨🇦’s universal system,
Patients with stage III colon cancer from:
🔹 lowest SES areas: 30% ↓ odds
🔹 most diverse areas: 28% ↓ odds
of receiving adjuvant chemo.
Equity in care ≠ equity in access.
📊👇 <a href="/uoftmedicine/">Temerty Medicine</a> <a href="/UofT_dlsph/">U of T Public Health</a> 
<a href="/HalletJulie/">Julie Hallet</a>
Surgical Oncology Insight (@surgoncinsight) 's Twitter Profile Photo

In Press: A retrospective study that identifies two serum biomarkers measured prior to neoadjuvant treatment that are able to discriminate N2 nodal status from N0 and N1 in patients with pancreatic ductal adenocarcinoma. ow.ly/1lXL50WbUT3 Flavio G Rocha, MD, FACS, FSSO @SKMaithel

In Press: A retrospective study that identifies two serum biomarkers measured prior to neoadjuvant treatment that are able to discriminate N2 nodal status from N0 and N1 in patients with pancreatic ductal adenocarcinoma.

ow.ly/1lXL50WbUT3

<a href="/FlavioRochaMD/">Flavio G Rocha, MD, FACS, FSSO</a>
@SKMaithel
AHPBA (@ahpba) 's Twitter Profile Photo

🚨 Don't miss this AHPBA webinar! "Pushing the Envelope and the Next Frontier for HCC & Cholangiocarcinoma" Monday, June 23 | 5:00–6:30pm CT Leading experts explore transplant, immunotherapy & targeted treatments. Register - survey.alchemer.com/s3/8249190/AHP… Sponsored by Genentech

🚨 Don't miss this AHPBA webinar!
"Pushing the Envelope and the Next Frontier for HCC &amp; Cholangiocarcinoma"
Monday, June 23 | 5:00–6:30pm CT
Leading experts explore transplant, immunotherapy &amp; targeted treatments.
Register - survey.alchemer.com/s3/8249190/AHP…
Sponsored by <a href="/genentech/">Genentech</a>